Robert Michael Dudley - May 19, 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
Chief Executive Officer, Director
Signature
/s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Stock symbol
RNAZ
Transactions as of
May 19, 2023
Transactions value $
$0
Form type
4
Date filed
5/19/2023, 08:06 PM
Previous filing
Dec 14, 2022
Next filing
Jun 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAZ Stock Option (right to buy) Award $0 +735K $0.00 735K May 19, 2023 Common Stock 735K $0.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time.